SEC Filing Summary: Synta Pharmaceuticals Corp.
Business Context and Reporting Period
This Form 8-K Current Report was filed by Synta Pharmaceuticals Corp. on May 6, 2013, regarding an event that occurred on May 5, 2013. The registrant is a Delaware corporation headquartered in Lexington, MA.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on a corporate governance event.
Material Changes
The material change reported is the resignation of Dr. Sumant Ramachandra as President, Research and Development, effective immediately on May 5, 2013. The resignation was cited as being for personal reasons.
Guidance, Outlook, and Risks
The filing text does not provide a clear value for financial guidance, future outlook, management commentary on operations, or specific risk factors beyond the personnel change.
Key Facts for Investor Verification
- Dr. Sumant Ramachandra resigned as President, Research and Development effective May 5, 2013.
- The resignation was attributed to personal reasons.
- The report was signed by Keith S. Ehrlich, Vice President, Finance and Administration and Chief Financial Officer.
- No financial data or operational metrics are included in this specific filing.